Your session is about to expire
← Back to Search
Combination Immunotherapy + Chemoradiation for Glioblastoma
Study Summary
This trial is testing a new combination of drugs to treat glioblastoma, a type of brain cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had an autoimmune disease that needed strong medications to control it in the past 5 years.You have received or are planning to receive certain types of treatments, such as tumor treatment fields or oncolytic viral treatment. You have also taken part in a clinical trial or used an experimental treatment within the past 28 days.You are allergic to cemiplimab or any of the ingredients in it.You need to have fully recovered from your previous brain surgery, as determined by the doctor in charge of the study.You are able to undergo an MRI scan without any problems or discomfort.You have received treatment with idelalisib in the past.You have had allergic reactions or severe sensitivity to antibody treatments in the past.You have previously received a treatment that blocks the PD-1/PD-Ligand 1 pathway.We agree that during the trial, men will not father a child, and women cannot be or become pregnant
- Group 1: Cohort A: Unmethylated MGMT Promoter
- Group 2: Cohort B: Methylated MGMT Promoter
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research being conducted in more than one country?
"This study is currently being administered at Huntsman Cancer Institute in Salt Lake City, Utah, Emory University School of Medicine in Atlanta, Georgia, and New york-Presbyterian Hospital/Weill Cornell Medical Center in New York, New York. In addition to these locations, there are 21 other trial sites."
How many people are being given the chance to participate in this research?
"As of right now, this study is not looking for any more participants. The clinical trial was first posted on May 31st 2018 and the listing was last updated on October 7th 2020. If you are interested in other studies, there are 458 trials for glioblastoma and 282 for INO-5401 that are currently enrolling patients."
Are we still able to enroll in this particular clinical trial?
"As can be seen on clinicaltrials.gov, this study is not presently looking for new patients to enroll. Although the study was last updated on 10/7/2022, it is not currently active. There are, however, 740 other trials which are still recruiting participants."
Has this research been conducted before?
"As of now, there are 282 active studies for INO-5401 being conducted in 50 countries and 1103 cities. The first study was sponsored by Schering-Plough back in 2002. That initial trial had 60 participants and completed its Phase 2 drug approval stage. In the 18 years since that first study, 406 more trials have been conducted."
Could you explain the most common reason why people use INO-5401?
"Other than nitrosourea treatment, INO-5401 can be used to treat advance directives, malignant neoplasms, and refractory advanced mycosis fungoides."
Are there other examples of INO-5401 being tested in a laboratory setting?
"As of now, there are 282 active clinical trials researching INO-5401 with 29 trials in Phase 3. While most of the trials for INO-5401 are running out of Seoul, Songpa, there are 6609 locations running trials for INO-5401."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger